Unnamed: 0,title,date,stock,sentiment
164040.0,"Biocept Shares Tick Higher Following Co. Tweet '...a new 15-minute scan, known as the prostagram, may replace rectal examinations for detecting #prostatecancer...'",2020-05-29 10:10:00-04:00,BIOC,positive
164041.0,Biocept Announces Data For Cerebrospinal Fluid At ASCO,2020-05-29 08:43:00-04:00,BIOC,neutral
164042.0,Shares of several healthcare companies are trading higher in sympathy with the overall market as equities rally on coronavirus vaccine hopes as well as a pickup in economic activity as some US states reopen businesses.,2020-05-26 11:58:00-04:00,BIOC,positive
164043.0,"Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020",2020-05-20 08:12:00-04:00,BIOC,neutral
164044.0,Biocept Highlights Release of its Target Selector BRAF Kit For Clients' Use In Their Own Laboratories,2020-05-14 08:11:00-04:00,BIOC,neutral
164045.0,"Biocept Q1 EPS $(0.110) Up From $(0.610) YoY, Sales $1.447M Miss $1.910M Estimate",2020-05-13 16:10:00-04:00,BIOC,negative
164046.0,Biocept Reports CE-IVD Mark For Its Target Selector EGFR Molecular Assay Kit In Europe,2020-04-28 08:06:00-04:00,BIOC,neutral
164047.0,"Biocept Highlights Launch Of Research-Use-Only Kits Allowing Labs To Utilize Co.'s Target Selector Assay Kits To Detect, FFPE Tissue, ctDNA",2020-04-20 08:19:00-04:00,BIOC,neutral
164048.0,Biocept Launches Line Of Molecular Assay Kits For Detection Of Key Oncogene Mutations Based On Its Proprietary Target Selector Technology Validated For Use In Both Tissue And Blood Samples,2020-04-20 08:06:00-04:00,BIOC,positive
164049.0,Biocept Prices 22.3M Common Stock Offering At $0.46/Share,2020-04-14 09:08:00-04:00,BIOC,neutral
164050.0,Biocept shares are trading higher after the company said it has a coronavirus test and will begin accepting physician orders this week.,2020-04-13 07:52:00-04:00,BIOC,positive
164051.0,"Biocept Shares Spike To Session High, Up 17%; Traders Circulate Co. Website Suggesting Co. Will Support Health Efforts, Related To Coronavirus Testing",2020-04-09 14:25:00-04:00,BIOC,positive
164052.0,Biocept's Granted Brazil Patent For Target Selector Oncogene Mutation Enrichment And Detection Platform,2020-04-09 08:17:00-04:00,BIOC,positive
164053.0,"Biocept Reports Australian Patent Issued For Primer-Switch Mutation Detection, Amplification Platform",2020-04-02 08:16:00-04:00,BIOC,neutral
164054.0,Biocept Enters Into Laboratory Services Agreement With Second California-Based Independent Physician Association,2020-03-26 08:14:00-04:00,BIOC,positive
164055.0,Biocept shares are trading higher after the company reported better-than-expected Q4 sales results.,2020-03-25 16:16:00-04:00,BIOC,positive
164056.0,"Biocept Q4 EPS $(0.2) Misses $(0.1) Estimate, Sales $1.8M Beat $1.7M Estimate",2020-03-25 16:09:00-04:00,BIOC,negative
164057.0,Biocept shares are trading lower after the company announced a common stock offering of 16 million shares at $0.41 per share.,2020-03-05 08:44:00-05:00,BIOC,positive
164058.0,Biocept Announces 16M Share Common Stock Offering To Be Priced At $0.41/Share,2020-03-05 08:33:00-05:00,BIOC,positive
164059.0,Sabby Management Reports 9.71% Passive Stake In Biocept As Of Mar. 2,2020-03-04 13:21:00-05:00,BIOC,positive
164060.0,Biocept Prices 23M Share Offering at $0.40/Share,2020-03-02 08:37:00-05:00,BIOC,positive
164061.0,Biocept Enters Into Laboratory Services Agreement With California-Based Independent Physician Association,2020-02-10 08:07:00-05:00,BIOC,positive
164062.0,Biocept Announces Validation And Availability Of Its Liquid Biopsy Platform For The Detection Of Actionable Cancer Biomarkers In Cerebrospinal Fluid,2020-01-14 08:09:00-05:00,BIOC,negative
164063.0,Biocept shares are trading higher after the company was awarded a U.S. patent for use of antibodies in combination with any solid surface to detect any target cell of interest.,2020-01-08 10:12:00-05:00,BIOC,positive
164064.0,"Biocept, Inc. Awarded United States Patent For Use Of Antibodies In Combination With Any Solid Surface To Detect Any Target Cell Of Interest",2020-01-08 09:00:00-05:00,BIOC,positive
164065.0,Biocept shares are trading lower after the company priced a 24.6 Million unit offering at $0.405 per unit.,2019-12-09 11:32:00-05:00,BIOC,neutral
164066.0,Biocept Prices 24.6M Unit Offering At $0.405/Unit,2019-12-09 09:19:00-05:00,BIOC,neutral
164067.0,Biocept's Liquid Biopsy CTC Testing For Breast Cancer To Be Featured In Poster Presentation At 2019 San Antonio Breast Cancer Symposium,2019-12-03 08:06:00-05:00,BIOC,negative
164068.0,Biocept Reports Launch Of Liquid Biopsy Test To Detect TRK Biomarkers In Blood Of Patients Diagnosed With Cancer,2019-11-21 08:17:00-05:00,BIOC,negative
164069.0,"Biocept Q3 EPS $(0.25) Beats $(0.27) Estimate, Sales $1.53M Beat $1.45M Estimate",2019-11-13 16:08:00-05:00,BIOC,neutral
164070.0,Biocept Receives Three Additional Patents Covering Its Antibody And Microchannel Technology And Enhanced Detection Of Cancer Cells,2019-08-13 08:18:00-04:00,BIOC,negative
164071.0,Biocept shares are trading lower after the company reported Q2 earnings.,2019-08-12 16:11:00-04:00,BIOC,neutral
164072.0,"Biocept Q2 EPS $(0.38) Up From $(2.7) YoY, Sales $1.191M Beat $1.02M Estimate",2019-08-12 16:09:00-04:00,BIOC,neutral
164073.0,Biocept shares are trading higher after the company announced it entered into a Laboratory Service Provider Agreement with Beacon Laboratory Benefit Solutions.,2019-07-22 09:43:00-04:00,BIOC,positive
164074.0,Biocept Announces Laboratory Services Provider Agreement With BeaconLBS,2019-07-22 08:07:00-04:00,BIOC,positive
164075.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday, June 19 2019",2019-06-19 09:53:00-04:00,BIOC,positive
164076.0,"Biocept shares are trading higher after the company announced the commercial launch of its Target Selector NGS Breast Panel, its multi-gene liquid biopsy panel specifically developed for breast cancer.",2019-06-18 10:19:00-04:00,BIOC,negative
164077.0,"Biocept Announces Commercial Launch Of Target Selector NGS Breast Panel, The Company's Second Multi-Gene Tumor-Specific Panel",2019-06-18 08:08:00-04:00,BIOC,neutral
164078.0,"Companies Which Will Be Presenting At LD Micro's 9th Annual Micro Invitational Tues., Jun. 4, 2019",2019-06-03 16:57:00-04:00,BIOC,neutral
164079.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wed., May 29, 2019",2019-05-29 10:06:00-04:00,BIOC,positive
164080.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., May 28, 2019",2019-05-28 10:13:00-04:00,BIOC,positive
164081.0,Biocept Awarded Patent In China For Its Circulating Tumor Cell Platform,2019-05-28 08:05:00-04:00,BIOC,neutral
164082.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wed., May 22, 2019",2019-05-22 10:13:00-04:00,BIOC,positive
164083.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., May 21, 2019",2019-05-21 09:23:00-04:00,BIOC,positive
164084.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Mon., May 20, 2019",2019-05-20 10:12:00-04:00,BIOC,positive
164085.0,Biocept shares are trading higher after the company announced clinical validation and the commercial launch of its target Selector Multi-Gene liquid biopsy panel for lung cancer.,2019-05-20 08:44:00-04:00,BIOC,negative
164086.0,"Biocept Q1 EPS $(0.61) Up From $(3.33) YoY, Sales $1.02M Up From $806.943K YoY",2019-05-08 16:29:00-04:00,BIOC,neutral
164087.0,Biocept Files For Up To 5.95M Share Common Stock By Selling Shareholders,2019-04-10 17:14:00-04:00,BIOC,positive
164088.0,"CORRECTION: Biocept Q4 EPS $(1.43), A Prior Headline Contained Last Year's EPS Figure",2019-03-28 16:12:00-04:00,BIOC,neutral
164089.0,"Biocept shares are trading higher after the company announced it would apply its EmpowerTC product to urology. Also, Maxim Group initiated coverage on the stock with a Buy rating and $3 price target.",2019-03-26 08:25:00-04:00,BIOC,positive
164090.0,"Biocept Reports Will Begin Commercializing Recently-Expanded Pathology Partnership Platform To Urology, Uropathology Practices",2019-03-26 08:06:00-04:00,BIOC,neutral
164091.0,"Maxim Group Initiates Coverage On Biocept with Buy Rating, Announces $3 Price Target",2019-03-26 08:03:00-04:00,BIOC,neutral
164092.0,Biocept Awarded Patent In Japan For The Capture Of Rare Cells Including CTCs From Any Biological Sample Of Interest with A Microchannel Device,2019-03-18 08:06:00-04:00,BIOC,positive
164093.0,Biocept shares are trading lower after the company priced an $8.2 million offering at $1.37 per share.,2019-03-15 11:32:00-04:00,BIOC,positive
164094.0,Biocept Prices $8.2M Offering At $1.37/Share,2019-03-15 09:01:00-04:00,BIOC,neutral
164095.0,"Biocept Highlights Expansion Of Pathology Partnership Offering For Liquid Biopsy, Including Addition Of 'Several Key Services'",2019-03-13 08:08:00-04:00,BIOC,neutral
164096.0,Biocept's Liquid Biopsy Test For ESR1 Biomarker Detection To Be Featured In Poster Presentation At 2019 AACR Annual Meeting,2019-03-04 08:16:00-05:00,BIOC,neutral
164097.0,Biocept Reports Collaboration With Providence Saint John's Health Center To Evaluate Cerebrospinal Fluid For Use With Liquid Biopsy Testing In Metastatic Cancer,2019-02-27 08:05:00-05:00,BIOC,negative
164098.0,Biocept Issues Letter To Stockholders,2019-02-20 08:16:00-05:00,BIOC,neutral
164099.0,Biocept 13G Filing From Anson Funds Mgmt. Shows New 9.9% Stake,2019-02-19 17:15:00-05:00,BIOC,neutral
164100.0,"Top 15 Most-Volatile Stocks For Thurs., Feb. 14, 2019 Via Benzinga's Securities Lending Volatility Index Powered By Tidal Markets",2019-02-14 10:29:00-05:00,BIOC,positive
164101.0,Top 15 Most-Volatile Stocks Via Benzinga's Securities Lending Volatility Index Powered By Tidal Markets,2019-02-13 12:40:00-05:00,BIOC,positive
164102.0,Biocept shares are trading lower after the company priced its 6.25 million share offering at $1.20 per share.,2019-02-08 09:04:00-05:00,BIOC,positive
164103.0,Biocept Prices 6.25M Share Offering At $1.20/Share,2019-02-08 08:46:00-05:00,BIOC,positive
164104.0,Biocept shares are trading higher after the company announced an agreement with Agiomix in which Agiomix will purchase Biocept's liquid biopsy kits for use in its laboratory assuming Agiomix can replicate results Biocept showed in its own testing.,2019-02-07 08:53:00-05:00,BIOC,positive
164105.0,Biocept Reports Deal With Agiomix FZ-LLC For Target Selector Liquid Biopsy Kits,2019-02-07 08:43:00-05:00,BIOC,neutral
164106.0,Biocept Shares Spike ~3% Over Last 20 Mins. As Traders Circulate Chatter A Deal For The Co. To Receive At Least $7.5M In Financing May Have Been Postponed,2019-01-30 13:28:00-05:00,BIOC,positive
164107.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Tues., Jan. 29, 2019",2019-01-29 09:28:00-05:00,BIOC,positive
164108.0,"Benzinga Pro's Top 7 Most-Searched Tickers For Morning Of Mon., Jan. 28, 2019",2019-01-28 08:58:00-05:00,BIOC,positive
164109.0,Biocept shares are trading higher after the company reported the launch of its liquid biopsy kits for detection of circulating tumor DNA.,2019-01-28 08:36:00-05:00,BIOC,negative
164110.0,Biocept Reports Launch Of Liquid Biopsy Kits For Use With Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA,2019-01-28 08:08:00-05:00,BIOC,negative
164111.0,Biocept 13G From Empery Asset Mgmt. Shows New 5.78% Stake,2019-01-24 16:50:00-05:00,BIOC,positive
164112.0,"Shares of Biocept are trading lower after the company announced a 990,000 share common stock offering at $2.25 per share.",2019-01-18 10:37:00-05:00,BIOC,positive
164113.0,Biocept Prices 990K Share Common Stock Offering At $2.25/Share,2019-01-18 09:04:00-05:00,BIOC,positive
164114.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Wed., Jan. 16, 2019",2019-01-16 15:04:00-05:00,BIOC,positive
164115.0,"Biocept shares are trading higher on heavy volume, now up 69% for the session despite no news; NOTE: The company has just 3.8 million shares in float, making the stock susceptible to low-float targeting and manipulation.",2019-01-16 11:24:00-05:00,BIOC,positive
164116.0,"Biocept Shares Halted On Circuit Breaker, Up 33.5%",2019-01-16 10:02:00-05:00,BIOC,positive
164117.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Tues., Jan. 15, 2019",2019-01-15 10:59:00-05:00,BIOC,positive
164118.0,"Biocept Shares Resume Trade, Up 180.9%",2019-01-14 15:22:00-05:00,BIOC,positive
164119.0,"Biocept Shares Halted On Second Circuit Breaker, Up 164.5%",2019-01-14 15:17:00-05:00,BIOC,positive
164120.0,"Biocept Shares Resume Trade, Up 123%",2019-01-14 15:15:00-05:00,BIOC,positive
164121.0,"Biocept Shares Halted On Circuit Breaker, Up 102.2%",2019-01-14 15:12:00-05:00,BIOC,positive
164122.0,Biocept shares are trading lower after the company filed for an offering of approximately 5.26 million common shares.,2018-12-19 08:59:00-05:00,BIOC,positive
164123.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Dec. 18, 2018",2018-12-18 15:26:00-05:00,BIOC,positive
164124.0,Biocept and Prognos Enter Into Software License And Laboratory Data Supply Agreement,2018-12-18 08:06:00-05:00,BIOC,positive
164125.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,BIOC,negative
164126.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,BIOC,negative
164127.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:21:00-05:00,BIOC,negative
164128.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Nov. 29, 2018",2018-11-30 10:27:00-05:00,BIOC,negative
164129.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 28, 2018",2018-11-29 10:59:00-05:00,BIOC,negative
164130.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,BIOC,negative
164131.0,"Biocept Q3 EPS $(2.42) Misses $(2.02) Estimate, Sales $761.591K Miss $950K Estimate",2018-11-13 16:42:00-05:00,BIOC,negative
164132.0,"Stocks Which Set New 52-Week Low Yesterday, October 31st",2018-11-01 10:37:00-04:00,BIOC,negative
164133.0,"Biocept Reports Obtained Japanese Patent For Target Selector Oncogene Mutation Enrichment, Detection Platform",2018-10-18 08:05:00-04:00,BIOC,neutral
164134.0,"Stocks Which Set New 52-Week Low Yesterday, October 10th",2018-10-11 09:11:00-04:00,BIOC,negative
164135.0,"Stocks Which Set New 52-Week Low Yesterday, October 3rd",2018-10-04 12:38:00-04:00,BIOC,negative
164136.0,"Stocks Which Set New 52-Week Low Yesterday, September 26th",2018-09-27 09:14:00-04:00,BIOC,negative
164137.0,"Stocks Which Set New 52-Week Low Yesterday, September 25th",2018-09-26 12:44:00-04:00,BIOC,negative
164138.0,Biocept 13G Filing From Lincoln Park Capital Shows New 9.99% Stake,2018-09-24 15:59:00-04:00,BIOC,neutral
164139.0,Biocept Awarded Patent in Hong Kong For Its Target Selector Platform Using Antibodies And A Microchannel To Perform Liquid Biopsy,2018-09-24 08:09:00-04:00,BIOC,positive
164140.0,"Biocept Prices ~762K Common Shares, Warrants; Warrants Priced At $3.285",2018-09-21 07:02:00-04:00,BIOC,positive
164141.0,Highmark Health's VITAL Innovation Program Is Testing Benefits Of Biocept's Liquid Biopsy Platform For Patients With Non-Small Cell Lung Cancer,2018-08-23 10:42:00-04:00,BIOC,positive
164142.0,"Biocept Resumes Trade, Now Up ~10% At $3.57/Share",2018-08-17 13:04:00-04:00,BIOC,neutral
164143.0,Biocept Shares Halted On Circuit Breaker,2018-08-17 12:59:00-04:00,BIOC,positive
164144.0,"Stocks Which Set New 52-Week Low Yesterday, August 15th",2018-08-16 11:15:00-04:00,BIOC,negative
164145.0,"Biocept Q2 EPS $(2.70) Beats $(3.30) Estimate, Sales $822.238K Miss $1.09M Estimate",2018-08-14 17:18:00-04:00,BIOC,negative
164146.0,Biocept Reports $11.6M in Expected Gross Proceeds from Recently Expired Rights Offering,2018-08-09 08:30:00-04:00,BIOC,negative
164147.0,Biocept Announces Agreement With Managed Care Plan To Study The Benefits Of Implementing Liquid Biopsy To Improve Patient Outcomes And Lower Healthcare Costs,2018-08-06 08:08:00-04:00,BIOC,positive
164148.0,Biocept Awarded Patent In Canada For Its Target Selector CTC Platform,2018-08-02 08:21:00-04:00,BIOC,positive
164149.0,Biocept Shares Up 9.3% Premarket After Co. Was Granted European Patent For Target Selector Oncogene Mutation Enrichment And Detection Platform; Patent Provides Intellectual Property Protection In Seven European Countries,2018-07-31 09:29:00-04:00,BIOC,positive
164150.0,Biocept Announces It Has Been Granted European Patent For Target Selector Oncogene Mutation Enrichment And Detection Platform,2018-07-31 08:14:00-04:00,BIOC,positive
164151.0,"Biocept Reports Collaboration With UC San Diego Health's Moores Cancer Center To Study Feasibility Of Liquid Biopsy To Predict Disease Recurrence In Solid Tumors, Response To Therapy",2018-07-23 08:20:00-04:00,BIOC,negative
164152.0,Biocept Shares Spike 15% As Traders Circulating EPO.org Alert On European Patent Specification Related To Co.'s Method For Detecting Nucleic Acid Sequence Variants,2018-07-12 15:22:00-04:00,BIOC,positive
164153.0,"Biocept Continues Higher, Up ~40%",2018-07-11 10:42:00-04:00,BIOC,neutral
164154.0,"Biocept Shares Halted On Circuit Breaker, Up 14.5% Over Last Few Mins., Up 24.5% For Session",2018-07-11 10:33:00-04:00,BIOC,positive
164155.0,Biocept Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering,2018-07-11 09:02:00-04:00,BIOC,neutral
164156.0,"Biocept On Friday Announced Announced 1-For-30 Reverse Stock Split And Stock Will Begin Trading On Split-Adjusted Basis Today; Some Platforms May Show Very Large Gain, Ignore",2018-07-10 09:31:00-04:00,BIOC,positive
164157.0,Biocept Highlights Recent Progress and Outlines Near-Term Strategic Priorities in CEO Letter to Stockholders,2018-06-25 08:11:00-04:00,BIOC,positive
164158.0,Biocept Shares Down 22.7% Premarket After Co. Late Tuesday Reported Mixed Q1 Results,2018-05-16 08:58:00-04:00,BIOC,positive
164159.0,"Biocept Q1 EPS $(0.11) Misses $(0.09) Estimate, Sales $1.683M Beat $1.1M Estimate",2018-05-15 16:10:00-04:00,BIOC,negative
164160.0,Biocept Obtains Patent for its Target Selector Molecular Biomarker Technology in China,2018-03-29 09:09:00-04:00,BIOC,neutral
164161.0,"Biocept Reports Q4 EPS $(0.18) Misses $(0.17) Est., Sales $1M Misses $1.16M Est.",2018-03-28 16:10:00-04:00,BIOC,negative
164162.0,"Biocept Reports Technology, Commercial Collaboration With Thermo Fisher Scientific",2018-03-28 08:06:00-04:00,BIOC,neutral
164163.0,"Biocept Shares Spike To Session Highs Over Last Few Mins., Now Up 21.7% For Session",2018-02-28 14:40:00-05:00,BIOC,positive
164164.0,Biocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector Platform,2018-02-05 08:06:00-05:00,BIOC,neutral
164165.0,"Biocept Prices 33.33M Share Common Stock, Warrant Offering At $0.45/Share",2018-01-26 06:34:00-05:00,BIOC,positive
164166.0,Biocept Shares Down ~9%; Earlier 8-K Filing Shows Co. Received Delisting Warning From NASDAQ,2018-01-23 14:14:00-05:00,BIOC,negative
164167.0,"Biocept Reports Study Showed Incorporation Of Thermo Fisher QuantStudio 5 PCR Instrument Into Target Selector Platform Improves Sensitivity, Specificity In Detection Of Lung Cancer Biomarkers",2018-01-09 08:18:00-05:00,BIOC,negative
164168.0,"Biocept Obtains Patent in Australia for its Molecular Biomarker Technology For the Detection of Cancer-Associated Mutations in Blood, Tissue, and Other Biological Sources",2018-01-04 08:05:00-05:00,BIOC,neutral
164169.0,Sabby Management Reports 9.2% Stake In Biocept,2017-12-06 10:50:00-05:00,BIOC,neutral
164170.0,Biocept Prices 4.93M Share Offering at $0.68/Share,2017-12-06 08:05:00-05:00,BIOC,positive
164171.0,Biocept Issued a Patent for its Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform,2017-12-05 08:18:00-05:00,BIOC,neutral
164172.0,"Biocept, UC San Diego Medical Center Report Clinical Study Partnership to Show Utility of Biocept's Liquid Biopsy Test in Immunotherapy",2017-11-28 08:06:00-05:00,BIOC,neutral
164173.0,"Biocept Reports Q3 EPS $(0.57) vs $(0.20) In Prior Year Period, Sales $1.047M vs $1.111M In Prior Year Period",2017-11-09 16:27:00-05:00,BIOC,neutral
164174.0,Biocept Reports Launch Of Pathology Partnership Initiative Expanding Access Of Proprietary Liquid Biopsy Testing To Community Members,2017-10-18 08:06:00-04:00,BIOC,neutral
164175.0,"Biocept, UT Southwestern Medical Center Report Clinical Study to Profile and Monitor Non-Small Cell Lung Cancer Patients with ALK Rearrangements",2017-08-17 08:08:00-04:00,BIOC,negative
164176.0,"Biocept Reports Exclusive Distribution Deal With VWR: Co.'s Blood-Collection Tubes Validated To Preserve ctDNA For Up to 96 Hours At Room Temp., Allowing Shipping Of Samples From Regions Around The World; No Terms Disclosed",2017-08-14 08:15:00-04:00,BIOC,positive
164177.0,"Biocept Reports Q2 Loss/Share $(0.21) vs. $(0.60) In Same Qtr. Last Year, Sales $1.3M vs. $663K YoY",2017-08-10 16:22:00-04:00,BIOC,neutral
164178.0,Biocept Reports Private Placement of $2.2M of Common Stock with Ally Bridge LB Healthcare Master Fund,2017-08-10 08:15:00-04:00,BIOC,neutral
164179.0,Biocept Enters into Preferred Provider Agreement with Scripps Health Plan Expanding Patient Coverage for its Liquid Biopsy Platform,2017-08-07 08:16:00-04:00,BIOC,positive
164180.0,"Biocept Reports Expansion Of Commercial Offering Of Clinically Actionable Biomarker Assays, Launches Liquid Biopsy Test For Progesterone Receptor Detection",2017-07-14 08:06:00-04:00,BIOC,neutral
164181.0,"Chardan Capital Initiates Coverage On Biocept with Buy Rating, Announces $2.50 Price Target",2017-06-02 06:11:00-04:00,BIOC,neutral
164182.0,Biocept Awarded US Patent with Broad Claims for Antibody Capture of Targets of Interest on Any Solid Surface Including CTCs and Other Materials Shed by Solid Tumors into Blood,2017-05-22 08:06:00-04:00,BIOC,positive
164183.0,Biocept Awarded Additional Patent in Japan Expanding IP Estate to 19 Issued Patents Protecting Target Selector Liquid Biopsy Platform,2017-04-18 08:06:00-04:00,BIOC,positive
164184.0,Biocept Enters Direct Offering Agreement For 4.32M Shares To Purchasers At $2.15/Share,2017-03-30 16:14:00-04:00,BIOC,positive
164185.0,Biocept Prices 4.32M Shares At $2.15/Share,2017-03-28 09:11:00-04:00,BIOC,positive
164186.0,"Biocept, Catalyst Pharma Report Collaboration for Providing Liquid Biopsy Test for Small Cell Lung Cancer to Patients with LEMS, No Terms Disclosed",2017-03-14 08:06:00-04:00,BIOC,negative
164187.0,Biocept Shares Up 19.4% Following Yesterday's Earnings,2017-03-08 08:45:00-05:00,BIOC,positive
164188.0,"Biocept Reports Q4 EPS $(0.27) vs. YoY $(0.73), Sales $1.29M vs. YoY $218K",2017-03-07 16:10:00-05:00,BIOC,neutral
164189.0,"Biocept's CEO Issues Letter to Stockholders, Highlights Drivers For 2017",2017-02-09 08:05:00-05:00,BIOC,neutral
164190.0,Biocept Awarded Patent in Australia for Use of Antibodies in Microchannels to Capture Circulating Tumor Cells and Other Rare Cells,2017-01-19 09:05:00-05:00,BIOC,neutral
164191.0,Biocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois,2016-01-12 07:04:00-05:00,BIOC,positive
164192.0,Lung Cancer Study Demonstrates Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy Platform in Detecting EGFR Mutation in Plasma with 93% Concordance with Tissue Biopsy,2015-11-05 07:07:00-05:00,BIOC,negative
164193.0,Biocept Announces Allowance of U.S. Patent DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS,2015-09-09 07:08:00-04:00,BIOC,neutral
164194.0,"H.C. Wainwright Initiates Coverage on Biocept at Buy, Announces $4.00 PT",2015-08-19 07:05:00-04:00,BIOC,neutral
164195.0,Biocept's Blood-based Liquid Biopsy for NSLC Highlighted in American Society of Clinical Oncology (ASCO) Abstract,2015-05-28 07:12:00-04:00,BIOC,neutral
164196.0,Study Highlights Value of Biocept's Blood-Based Diagnostic for Determining Hormonal Status in Patients With Metastatic Breast Cancer,2015-02-23 08:40:00-05:00,BIOC,negative
164197.0,"Aegis Capital Initiates Coverage on Biocept Labs at Buy, Announces $16.00 PT",2014-06-03 09:11:00-04:00,BIOC,neutral
164198.0,UPDATE: Benchmark Terminates Coverage on BioClinica Following Acquisition by JLL Partners,2013-03-18 08:13:00-04:00,BIOC,neutral
164199.0,"Benchmark Terminates Hold Rating on BioClinica, Inc",2013-03-15 16:31:00-04:00,BIOC,neutral
164200.0,Affiliate of JLL Partners Commences Tender Offer for BioClinica at $7.25/Share,2013-02-11 07:33:00-05:00,BIOC,neutral
164201.0,"BioClinica, Inc Reports Q4 EPS of $0.10 vs $0.09 Est; Revenue of $27.60M vs $24.62M Est",2013-02-06 07:53:00-05:00,BIOC,neutral
164202.0,UPDATE: Benchmark Downgrades BioClinica to Hold Following Sale Agreement,2013-01-31 07:31:00-05:00,BIOC,positive
164203.0,"Benchmark Downgrades BioClinica, Inc to Hold, Maintains $7.25 PT",2013-01-31 06:42:00-05:00,BIOC,neutral
164204.0,"Benzinga's M&A Chatter for Wednesday January 30, 2013",2013-01-30 19:03:00-05:00,BIOC,neutral
164205.0,BioClinica Shares to Resume Trading at 8AM EST,2013-01-30 07:38:00-05:00,BIOC,positive
164206.0,BioClinica to Be Purchased by JLL Partners for $7.25/Share,2013-01-30 07:37:00-05:00,BIOC,neutral
164207.0,BioClinica Halted News Pending,2013-01-30 07:25:00-05:00,BIOC,neutral
164208.0,"Benchmark  Maintains BioClinica at Buy, Raises PT from $8 to $9",2012-10-18 08:46:00-04:00,BIOC,neutral
164209.0,BioClinica Expands Osteoarthritis Trial  Imaging Support,2012-10-16 06:50:00-04:00,BIOC,positive
164210.0,BioClinica Reports Q2 EPS $0.06 vs $0.06 Est; Revenues $19.1M vs $22.61M Est,2012-08-08 07:03:00-04:00,BIOC,neutral
164211.0,"UPDATE: Benchmark Initiates BioCLinica with Buy, $8 PT as Possible M&A Target",2012-07-03 12:22:00-04:00,BIOC,neutral
164212.0,Two Winning Trades Based on Analyst Calls ,2012-07-03 12:22:00-04:00,BIOC,positive
164213.0,Benzinga's Top Initiations,2012-07-03 07:52:00-04:00,BIOC,positive
164214.0,"The Benchmark Company Initiates Coverage on BioClinica at Buy, Announces PT of $8",2012-07-03 06:38:00-04:00,BIOC,neutral
164215.0,BioClinica Partners with Paragon Solutions to Create Clinical Architecture   ,2012-04-17 08:35:00-04:00,BIOC,positive
164216.0,From Earlier: BioClinica Partners With Mirada Medical ,2012-03-30 08:24:00-04:00,BIOC,neutral
164217.0,A Peek Into The Market Before The Trading Starts,2012-03-23 07:18:00-04:00,BIOC,neutral
164218.0,BioClinica Partners with NextDocs to Streamline Clinical Trial Submission Process   ,2012-03-23 07:00:00-04:00,BIOC,neutral
164219.0,A Peek Into The Market Before The Trading Starts,2012-03-05 07:21:00-05:00,BIOC,neutral
164220.0,Grünenthal Selects BioClinica OnPoint Clinical Trial Management System   ,2012-03-05 06:38:00-05:00,BIOC,neutral
164221.0,UPDATE: Benchmark Raises Price Target on BioClinica to $8,2012-01-17 08:40:00-05:00,BIOC,neutral
164222.0,BioClinica WebSend Effects Rapid Change in Clinical Trial Image Management with Adoption Rate Surpassing 90%   ,2011-09-21 06:39:00-04:00,BIOC,neutral
164223.0,Paragon Solutions and BioClinica Reveal Findings from First Clinical Trial Supplies Industry Forecasting Survey ,2011-06-30 10:55:00-04:00,BIOC,positive
164224.0,BioClinica Inks Seven New Trident IWR Deals in First Quarter 2011   ,2011-04-07 07:03:00-04:00,BIOC,neutral
164225.0,"NASDAQ Stocks Hitting 52-Week Highs (BRNC, BIOC, ATEA, TORM)",2011-03-23 10:15:00-04:00,BIOC,neutral
164226.0,BioClinica CTMS Achieves Growing Market Acceptance   ,2011-03-23 08:07:00-04:00,BIOC,positive
164227.0,BioClinica Announces Share Repurchase of $2.0M,2010-12-17 07:19:00-05:00,BIOC,positive
164228.0,BioClinica Responds to Shareholder Letter (BIOC)  ,2010-09-30 15:18:00-04:00,BIOC,neutral
164229.0,Garry D. Johnson Joins BioClinica as Senior Vice President ,2010-09-08 09:35:00-04:00,BIOC,neutral
164230.0, BioClinica  (BIOC)  Announces  2009 Q3 Financial Results,2009-11-04 07:12:00-05:00,BIOC,neutral
